Board of Directors
Laxxon Medical is a global leader of smart drug delivery systems in the pharmaceutical industry, pioneering a new generation of advanced oral drug delivery forms with Laxxon's additive manufacturing technology platform, SPID®-Technology. Laxxon is dedicated to revolutionizing the pharmaceutical industry by driving innovation with better, smarter drug delivery solutions.
Laxxon owns the exclusive worldwide rights for the development, production and commercialization for complex drug delivery systems based on our innovative additive manufacturing process.
The future of pharmaceuticals.
What we do
Together with our CDMO partner Adare, we are developing advanced oral dosage forms to unlock clinical and commercial opportunities across the world.
Laxxon's pipeline includes 4+ ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house assets. Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of 230 patents and patent applications with more than 5,500 patent claims.
About Laxxon Medical
Strategic Commercialization
SPID®-Technology unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities in drug development and commercialization.
Laxxon’s business model is based upon a three-solution framework:
With SPID®-Technology, Laxxon can develop and manufacture advanced versions of new and existing pharmaceutical drugs while extending and adding new patent protection through the technology transfer process. Laxxon can fully utilize the FDA’s 505b(2) regulatory pathway in the US and Hybrid applications under article 10(3) of Directive 2001/83/EC in the EUR, which fast tracks product routes to market.
Laxxon Leadership
Laxxon was founded in 2017 by a team of medical and business professionals with 20+ years of experience in the pharmaceutical industry. Our highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners including R&D, IP, and regulatory services. Laxxon is headquartered in New York City with research and development facilities in Jena, Germany.
Board of Directors
Edward Kay
Board Member
Edward W. Kay Jr. has been a director of the Vuzix Corporation, manufacturer and sale of VR and optical devices since April 2016, and Lead Independent Director since February 2022. Mr. Kay is a Certified Public Accountant who spent his 33-year career with PricewaterhouseCoopers LLP (PwC) working with companies in various industries...
Christof Bircher
Board Member
Christof Bircher has a background in chemistry and a long experience in marketing, digital transformation and general management. He served as the Director of Digital Transformation, Marketing and Business Development and an executive board member at Büchi AG, a leading provider of high-quality laboratory equipment as well as in various general management roles...
Nneka Ukpai
Board Member
Nneka Ukpai is a financial technology innovator working with Pop Venture to democratize access to private capital markets. Nneka previously served as the Head of Financial Innovation at Better, a leading homeownership platform and the fastest fintech to surpass $100Bn in funded volume. Prior to Better, Nneka was a senior attorney at a renowned global law firm where she helped C-Suite executives...
Scientific Advisory Board
Ulrich S. Schubert
Ph.D.
Dr. Schubert is a chemist and professor for Organic and Macromolecular Chemistry at the Friedrich Schiller University Jena. Dr. Schubert studied chemistry at the universities of Frankfurt am Main, Virginia Commonwealth University (Richmond, USA) and Bayreuth, before receiving his doctorate from Bayreuth in a joint PhD thesis...
Ulrich Granzer
Ph. D.
Dr. Granzer graduated as a pharmacist in 1984 from the University of Marburg, followed by Ph.D. studies during which he also acted as lecturer for pharmaceutical chemistry. In 1988 he served in the German Air Force and advanced to the rank of a captain with responsibility for drug safety. In 1989, he started his industry career...
Kurt van Scoik
Ph. D.
Dr. Van Scoik studied pharmacy before obtaining his doctorate in pharmaceutics at the University of Wisconsin-Madison in 1987. Dr. Van Scoik gained ten years' experience at Abbott Laboratories in the Pharmaceutical Products Division, where his research involved solving problems related to the development of new drugs and new solid...
SPID®-Technology
Based on our technology partner Exentis Group's proprietary 3D screen printing technology platform, Laxxon’s SPID®-Technology (Screen Printing Innovational Drug Technology) is a cutting-edge patented additive manufacturing technology which enables intelligent pharmaceutical application forms, such as oral, transdermal, and implantable dosages, through geometric shaping and heterogeneous distribution of active pharmaceutical ingredients (APIs).
SPID®-Technology is capable of printing small batches for R&D, up to commercial-scale production (up to 1.5MM units per day) without the need to change the manufacturing process.
